Literature DB >> 1394801

Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin.

G R Fisher1, L H Patterson.   

Abstract

The MCF-7 cell S9 fraction and whole MCF-7 cells can mediate one-electron-redox cycling of doxorubicin, giving rise to concomitant oxidation of reduced nicotinamide adenine dinucleotide phosphate (NADPH), formation of a drug semiquinone free radical, consumption of molecular oxygen and formation of superoxide anions and hydroxyl radicals. Doxorubicin redox cycling was consistent with DNA strand breakage and cell kill in MCF-7 cells. In contrast, no evidence for redox cycling was found for mitoxantrone (MIT), CI941 or ametantrone (AMET) in MCF-7 cells. Despite the absence of redox cycling, the CI941, MIT, and AMET concentrations resulting in 50% mortality (LC50; 1.5 x 10(-10), 5.2 x 10(-9) and 1.2 x 10(-6) M, respectively) of MCF-7 cells were lower than that of DOX (3.0 x 10(-6) M). Furthermore, the higher cytotoxicity of MIT and CI941 as compared with AMET or DOX was associated with greater efficiency in inducing DNA strand breakage in MCF-7 cells as determined by alkaline elution. Since MIT and CI941 proved to be the most potent DNA-damaging and cytotoxic agents in this study, the ability of DOX to undergo redox cycling does not appear to confer increased cytotoxic potential on this agent. The present study revealed several important aspects with regards to the structural modification of anthraquinone antitumour agents. Firstly, the C1 and C4 positioning of the hydroxyethylamino side chains on MIT, CI941 and AMET is associated with a lack of flavin reductase-mediated activation of these agents. Secondly, the possession of a C5 or C8 aromatic hydroxyl group appears to be intimately involved in the enhanced DNA strand breakage and cytotoxic potency of MIT and CI941, since AMET does not possess these groups. These findings indicate that future development of quinone antitumour agents should concentrate on compounds that do not undergo redox cycling but do possess aromatic hydroxyl groups, since the latter appear to be responsible for the enhanced cytotoxicity of MIT and CI941.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1394801     DOI: 10.1007/bf00685596

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  61 in total

1.  Characteristics of the interaction of anthrapyrazole anticancer agents with deoxyribonucleic acids: structural requirements for DNA binding, intercalation, and photosensitization.

Authors:  J A Hartley; K Reszka; E T Zuo; W D Wilson; A R Morgan; J W Lown
Journal:  Mol Pharmacol       Date:  1988-03       Impact factor: 4.436

2.  Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells.

Authors:  P J Smith; S A Morgan; M E Fox; J V Watson
Journal:  Biochem Pharmacol       Date:  1990-11-01       Impact factor: 5.858

3.  Mitoxantrone affects topoisomerase activities in human breast cancer cells.

Authors:  M D Crespi; S E Ivanier; J Genovese; A Baldi
Journal:  Biochem Biophys Res Commun       Date:  1986-04-29       Impact factor: 3.575

4.  Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone.

Authors:  M E Fox; P J Smith
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

5.  Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration.

Authors:  W T Bellamy; R T Dorr; W S Dalton; D S Alberts
Journal:  Cancer Res       Date:  1988-11-15       Impact factor: 12.701

6.  The reductive metabolism of diaziquone (AZQ) in the S9 fraction of MCF-7 cells: free radical formation and NAD(P)H: quinone-acceptor oxidoreductase (DT-diaphorase) activity.

Authors:  G R Fisher; P L Gutierrez
Journal:  Free Radic Biol Med       Date:  1991       Impact factor: 7.376

7.  Effect of sodium chloride concentration on adriamycin and N-trifluoroacetyladriamycin-14-valerate (AD32)-induced cell killing and DNA damage in Chinese hamster V79 cells.

Authors:  G Iliakis; W Lazar
Journal:  Cancer Res       Date:  1987-04-01       Impact factor: 12.701

8.  Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.

Authors:  S de Jong; J G Zijlstra; E G de Vries; N H Mulder
Journal:  Cancer Res       Date:  1990-01-15       Impact factor: 12.701

9.  Detection of free radicals during the cellular metabolism of adriamycin.

Authors:  M J Turner; D B Everman; S P Ellington; C E Fields
Journal:  Free Radic Biol Med       Date:  1990       Impact factor: 7.376

10.  Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin.

Authors:  L A Zwelling; S Michaels; L C Erickson; R S Ungerleider; M Nichols; K W Kohn
Journal:  Biochemistry       Date:  1981-11-10       Impact factor: 3.162

View more
  6 in total

1.  Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathy.

Authors:  N Iliskovic; B B Hasinoff; K L Malisza; T Li; I Danelisen; P K Singal
Journal:  Mol Cell Biochem       Date:  1999-06       Impact factor: 3.396

Review 2.  Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.

Authors:  L H Patterson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 3.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

4.  Mitoxantrone impairs proteasome activity and prompts early energetic and proteomic changes in HL-1 cardiomyocytes at clinically relevant concentrations.

Authors:  Vera Marisa Costa; João Paulo Capela; Joana R Sousa; Rute P Eleutério; Patrícia R S Rodrigues; José Luís Dores-Sousa; Rui A Carvalho; Maria Lourdes Bastos; José Alberto Duarte; Fernando Remião; M Gabriela Almeida; Kurt J Varner; Félix Carvalho
Journal:  Arch Toxicol       Date:  2020-09-07       Impact factor: 5.153

5.  Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours.

Authors:  B C Goh; E E Vokes; A Joshi; M J Ratain
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

6.  Dual Function of Gold Nanoparticles in Synergism with Mitoxantrone and Microwave Hyperthermia Against Melanoma Cells

Authors:  Ahmad Shanei; Ameneh Sazgarnia; Elham Dolat; Leila Hojaji-Najafabadi; Mohammadreza Sehhati; Milad Baradaran-Ghahfarokhi
Journal:  Asian Pac J Cancer Prev       Date:  2017-11-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.